New hope for untreated advanced lung cancer patients

NCT ID NCT05565378

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study is testing new combinations of immunotherapy drugs for people with advanced non-small cell lung cancer who haven't had any prior treatment. It focuses on patients whose tumors have high levels of a protein called PD-L1. The main goal is to see how safe these drug combinations are and how well patients tolerate them.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Plantation, Florida, 33322, United States
GSK Investigational Site

Albuquerque, New Mexico, 87131, United States
GSK Investigational Site

Chattanooga, Tennessee, 37404, United States
GSK Investigational Site

Morgantown, West Virginia, 26506, United States
GSK Investigational Site

Buenos Aires, C1426ABP, Argentina
GSK Investigational Site

Cipoletti Rio Negro, R8324CVE, Argentina
GSK Investigational Site

Ciudad Autonoma de Buenos Aire, 1414, Argentina
GSK Investigational Site

Ciudad Autonoma de Buenos Aire, C1426AGE, Argentina
GSK Investigational Site

Florida, 1602, Argentina
GSK Investigational Site

Mar del Plata, 7600, Argentina
GSK Investigational Site

San Juan, J5402DIL, Argentina
GSK Investigational Site

Santa Fe, 3000, Argentina
GSK Investigational Site

Wilrijk, 2650, Belgium
GSK Investigational Site

Barretos, 14784-400, Brazil
GSK Investigational Site

Porto Alegre, 90610-000, Brazil
GSK Investigational Site

São Paulo, 01246-000, Brazil
GSK Investigational Site

Vitória, 29043-260, Brazil
GSK Investigational Site

Oulu, 90220, Finland
GSK Investigational Site

Tampere, 33520, Finland
GSK Investigational Site

Turku, 20520, Finland
GSK Investigational Site

Vaasa, 65130, Finland
GSK Investigational Site

Bordeaux, 33076, France
GSK Investigational Site

Caen, 14033, France
GSK Investigational Site

Marseille, 13009, France
GSK Investigational Site

Quimper, 29107, France
GSK Investigational Site

Strasbourg, 67091, France
GSK Investigational Site

Berlin, 13125, Germany
GSK Investigational Site

Essen, 45147, Germany
GSK Investigational Site

Großhansdorf, 22927, Germany
GSK Investigational Site

Heidelberg, 69126, Germany
GSK Investigational Site

Jena, 07747, Germany
GSK Investigational Site

Athens, 11528, Greece
GSK Investigational Site

Haidari - Athens, 12462, Greece
GSK Investigational Site

Larissa, 41110, Greece
GSK Investigational Site

PapagosAthens, 115 27, Greece
GSK Investigational Site

Pylaia Thessaloniki, 57001, Greece
GSK Investigational Site

Thessaloniki, 54645, Greece
GSK Investigational Site

Thessaloniki, 57010, Greece
GSK Investigational Site

Budapest, H-1121, Hungary
GSK Investigational Site

Gyöngyös, 3200, Hungary
GSK Investigational Site

Tatabánya, 2800, Hungary
GSK Investigational Site

Avellino, 83100, Italy
GSK Investigational Site

Bergamo, 24125, Italy
GSK Investigational Site

Genova, 16132, Italy
GSK Investigational Site

Pisa, 57124, Italy
GSK Investigational Site

Verona, 37045, Italy
GSK Investigational Site

Chiba, 277-8577, Japan
GSK Investigational Site

Fukuoka, 812-8582, Japan
GSK Investigational Site

Hyōgo, 673-8558, Japan
GSK Investigational Site

Kanagawa, 241-8515, Japan
GSK Investigational Site

Osaka, 590-0197, Japan
GSK Investigational Site

Saitama, 350-1298, Japan
GSK Investigational Site

Guadalajara, 44280, Mexico
GSK Investigational Site

San Luis Potosí City, 78209, Mexico
GSK Investigational Site

Enschede, 7512 KZ, Netherlands
GSK Investigational Site

Groningen, 9728 NZ, Netherlands
GSK Investigational Site

Leeuwarden, 8934 AD, Netherlands
GSK Investigational Site

Utrecht, 3543 AZ, Netherlands
GSK Investigational Site

Lublin, 20-954, Poland
GSK Investigational Site

Prabuty, 82-550, Poland
GSK Investigational Site

Siedlce, 08-110, Poland
GSK Investigational Site

Gaia, 4434-502, Portugal
GSK Investigational Site

Guimarães, 4835-044, Portugal
GSK Investigational Site

Lisbon, 1500-650, Portugal
GSK Investigational Site

Lisbon, 1998-018, Portugal
GSK Investigational Site

Porto, 4200-072, Portugal
GSK Investigational Site

Cape Town, 7570, South Africa
GSK Investigational Site

Parktown, 2193, South Africa
GSK Investigational Site

Incheon, 21565, South Korea
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 03722, South Korea
GSK Investigational Site

Suwon Gyeonggi-do, 442-723, South Korea
GSK Investigational Site

Badajoz, 06080, Spain
GSK Investigational Site

Badalona, 08916, Spain
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Las Palmas de Gran Canar, 35016, Spain
GSK Investigational Site

Madrid, 28027, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Málaga, 29010, Spain
GSK Investigational Site

PamplonaNavarra, 28027, Spain
GSK Investigational Site

Valencia, 46009, Spain
GSK Investigational Site

Valencia, 46026, Spain
GSK Investigational Site

Bangkok, 10210, Thailand
GSK Investigational Site

Chiang Mai, 50200, Thailand
GSK Investigational Site

Kho Hong Hat Yai, 90110, Thailand
GSK Investigational Site

Khon Kaen, 40002, Thailand
GSK Investigational Site

Pathum Thani, 12120, Thailand
GSK Investigational Site

Samsun, Atakum, 55200, Turkey (Türkiye)
GSK Investigational Site

Ankara, 06680, Turkey (Türkiye)
GSK Investigational Site

Ankara, 06800, Turkey (Türkiye)
GSK Investigational Site

Antalya, 07070, Turkey (Türkiye)
GSK Investigational Site

Istanbul, 34214, Turkey (Türkiye)
GSK Investigational Site

Abu Dhabi, 51900, United Arab Emirates
GSK Investigational Site

Abu Dhabi, United Arab Emirates
GSK Investigational Site

Middlesbrough, TS4 3BW, United Kingdom
GSK Investigational Site

Middlesex, HA6 2RN, United Kingdom
GSK Investigational Site

Wolverhampton, WV10 0QP, United Kingdom

Conditions

Explore the condition pages connected to this study.

LUNG CANCER (NON-SMALL CELL)